Due to their unique and versatile biochemical properties, ruthenium-based compounds have emerged as promising anticancer agents. Previous studies showed that three ruthenium(II) compounds: [Ru(pySH)(bipy)(dppb)]PF6 (1), [Ru(HSpym)(bipy)(dppb)]PF6 (2) and Ru[(SpymMe2)(bipy)(dppb)]PF6 (3) presented anticancer properties higher than doxorubicin and cisplatin and acted as human topoisomerase IB (Topo I) inhibitors. Here, we focused our studies on in vitro intestinal permeability and anticancer mechanisms of these three complexes. Caco-2 permeation studies showed that 1 did not permeate the monolayer of intestinal cells, suggesting a lack of absorption on oral administration, while 2 and 3 permeated the cells after 60 and 120 min, respectively. Complexes 2 and 3 fully inhibited Topo II relaxation activity at 125 µM. In previously studies, 3 was the most potent inhibitor of Topo I, here, we concluded that it is a dual topoisomerase inhibitor. Moreover, it presented selectivity to cancer cells when evaluated by clonogenic assay. Thus, 3 was selected to gene expression assay front MDA-MB-231 cells from triple-negative breast cancer (TNBC), which represents the highly aggressive subgroup of breast cancers with poor prognosis. The analyses revealed changes of 27 out of 84 sought target genes. PARP1 and PARP2 were 5.29 and 1.83 times down-regulated after treatment with 3, respectively. PARPs have been attractive antitumor drug targets, considering PARP inhibition could suppress DNA damage repair and sensitize tumor cells to DNA damage agents. Recent advances in DNA repair studies have shown that an approach that causes cell lethality using synthetic PARP-inhibiting drugs has produced promising results in TNBC.
Ruthenium compounds Triple negative breast cancer Topoisomerase PARP inhibitor
This is a preview of subscription content, log in to check access.
The authors gratefully acknowledge the financial support from the São Paulo Research Foundation (FAPESP Grants 2012/21529-7, 2016/22429-7 and 2016/16312-0), Coordinating Committee for Advancement of Higher Education Staff in Brazil (CAPES) and the Brazilian National Council of Technological and Scientific Development (CNPq).
Compliance with Ethical Standards
Conflict of interest
The authors declare that they have no conflicts of interest regarding the contents of this article.
Artursson P, Palm K, Luthman K (2001) Caco-2 monolayers in experimental and theoretical predictions of drug transport. Adv Drug Deliv Rev 46:27–43CrossRefGoogle Scholar
Demoro B, De Almeida RFM, Marques F et al (2013) Screening organometallic binuclear thiosemicarbazone ruthenium complexes as potential anti-tumour agents: cytotoxic activity and human serum albumin binding mechanism. Dalt Trans 42:7131–7146. https://doi.org/10.1039/c3dt00028aCrossRefGoogle Scholar
Denny WA, Baguley BC (2003) Dual topoisomerase I/II inhibitors in cancer therapy. Curr Top Med Chem 3:339–353CrossRefGoogle Scholar
Jaxel C, Kohn KW, Wani MC et al (1989) Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: evidence for a specific receptor site and a relation to antitumor activity. Cancer Res 49:1465–1469Google Scholar
Lajus TBP (2010) A utilização de inibidores de PARP na profilaxia e no tratamento do câncer de mama deficiente no gene BRCA1. Rev Ciênc Méd Biol 1:252–256Google Scholar
Lin JZ, Zou L, Fu CM et al (2013) Octanol/water partition coefficient and absorption kinetics of salidroside and tyrosol in rat intestine. Chin Tradi Pat Med 35:483–486Google Scholar
Lu Y, Mahato RI (2009) Pharmaceutical perspectives of cancer therapeutics. Springer Science & Business Media, New YorkCrossRefGoogle Scholar
Madden KR, Champoux JJ (1992) Overexpression of human topoisomerase I in baby hamster kidney cells: hypersensitivity of clonal isolates to camptothecin. Cancer Res 52:525–532Google Scholar
Magalhães LF, Mello-Andrade F, Pires WC et al (2017) cis-[RuCl(BzCN)(bipy)(dppe)]PF6 induces anti-angiogenesis and apoptosis by a mechanism of caspase-dependent involving DNA damage, PARP activation, and Tp53 induction in Ehrlich tumor cells. Chem Biol Interact 278:101–113. https://doi.org/10.1016/j.cbi.2017.09.013CrossRefGoogle Scholar
Min A, Im S-A, Kim DK et al (2015) Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells. Breast Cancer Res 17:33. https://doi.org/10.1186/s13058-015-0534-yCrossRefGoogle Scholar
Takagi T, Ramachandran C, Bermejo M et al (2006) A provisional biopharmaceutical classification of the top 200 oral drug products in the United States, Great Britain, Spain, and Japan. Mol Pharm 3:631–643CrossRefGoogle Scholar